Guideline Video

Guideline Resources

  • Title: Prevention of RSV Disease in Infants and Children
  • Society:  American Academy of Pediatrics
  • Publish Date: August 19, 2025
  • Overview
  • Full-text

Video Transcription

Today we’ll be going over the American Academy of Pediatrics’ newest policy statement on Prevention of RSV Disease in Infants and Children.

This policy statement goes over the recommended populations, equity considerations, and approved products. In today’s video we’ll just be going over key points, let’s get started. 

Starting with the recommended populations, the AAP recommends RSV immunization for:

  • infants <8 months of age born during or entering their first RSV season if:
    • pregnant parent did not receive RSVpreF vaccine during this pregnancy,
    • pregnant parent’s RSVpreF vaccination status is unknown, or
    • infant was born <14 days after the pregnant parent’s RSVpreF vaccination
  • infants and children 8 through 19 months of age at high risk of severe RSV disease and entering their second RSV season, regardless of the RSV vaccination status of the pregnant parent or the child’s prior receipt of nirsevimab or clesrovimab when <8 months of age in their first RSV season. High risk criteria include
    • Children with chronic lung disease of prematurity who required medical support at any time during the 6-month period before the start of the second RSV season
    • Children with severe immunocompromise 
    • Children with cystic fibrosis who have either:  manifestations of severe lung disease or  weight-for-length that is less than the 10th percentile 
    • American Indian or Alaska Native children

On to equity considerations:
American Indian and Alaska Native Children are included in the high-risk category, because they experience significantly higher rates of severe RSV disease and hospitalization, with children living in rural and reservation communities most impacted. Evidence supports that this increased risk is associated with social drivers of health, with specific attention to running water access, transportation difficulties, household crowding, and indoor air quality.

And last approved products:

  • Nirsevimab and clesrovimab are considered the first-line recommended immunization products for administration to infants to protect against medically attended RSV disease. They are long-acting monoclonal antibody products administered as a single dose for administration during an infant’s first RSV season. The AAP recommends any licensed RSV immunization product appropriate for age and health status and does not prefer one product over another
  • Palivizumab is a short-acting monoclonal antibody product that is administered in monthly doses during the RSV season. Palivizumab is no longer routinely recommended for use and will be discontinued as of December 31, 2025. 

And there you have it. Make sure to check out the full policy statement from The American Academy of Pediatrics and other related clinical decision support tools at guidelinecentral.com.

Copyright © 2025 Guideline Central, all rights reserved.